Azathioprine/6-mercaptopurine metabolism in ulcerative colitis: A guide to metabolite assessment—an evidence-based approach

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Ulcerative colitis (UC) and Crohn’s disease are chronic relapsing idiopathic inflammatory bowel disorders affecting over 1.7 million individuals in North America; about half have unremitting disease with symptoms of abdominal pain and diarrhea that impact patient’s quality of life and work- related productivity [1, 2]. It stands to reason that the major goal of therapy for physicians caring for patients with inflammatory bowel disease (IBD) is to achieve and sustain a long- term disease remission with effective evidence-based corticosteroid-sparing therapeutic approaches that minimize the risk of drug-related toxicity.

Original languageEnglish (US)
Title of host publicationMedical Therapy of Ulcerative Colitis
PublisherSpringer New York
Pages145-152
Number of pages8
ISBN (Electronic)9781493916771
ISBN (Print)9781493916764
DOIs
StatePublished - Jan 1 2014

Fingerprint

6-Mercaptopurine
Azathioprine
Ulcerative Colitis
North America
Drug-Related Side Effects and Adverse Reactions
Inflammatory Bowel Diseases
Crohn Disease
Abdominal Pain
Diarrhea
Adrenal Cortex Hormones
Quality of Life
Physicians
Therapeutics

Keywords

  • 6-Mercaptopurine metabolism
  • Azathioprine
  • Evidence-based
  • Metabolite assessment
  • Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Azathioprine/6-mercaptopurine metabolism in ulcerative colitis : A guide to metabolite assessment—an evidence-based approach. / Cuffari, Carmelo.

Medical Therapy of Ulcerative Colitis. Springer New York, 2014. p. 145-152.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{ed75e239d19d440a9cd091163f8d4102,
title = "Azathioprine/6-mercaptopurine metabolism in ulcerative colitis: A guide to metabolite assessment—an evidence-based approach",
abstract = "Ulcerative colitis (UC) and Crohn’s disease are chronic relapsing idiopathic inflammatory bowel disorders affecting over 1.7 million individuals in North America; about half have unremitting disease with symptoms of abdominal pain and diarrhea that impact patient’s quality of life and work- related productivity [1, 2]. It stands to reason that the major goal of therapy for physicians caring for patients with inflammatory bowel disease (IBD) is to achieve and sustain a long- term disease remission with effective evidence-based corticosteroid-sparing therapeutic approaches that minimize the risk of drug-related toxicity.",
keywords = "6-Mercaptopurine metabolism, Azathioprine, Evidence-based, Metabolite assessment, Ulcerative colitis",
author = "Carmelo Cuffari",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1677-1_12",
language = "English (US)",
isbn = "9781493916764",
pages = "145--152",
booktitle = "Medical Therapy of Ulcerative Colitis",
publisher = "Springer New York",

}

TY - CHAP

T1 - Azathioprine/6-mercaptopurine metabolism in ulcerative colitis

T2 - A guide to metabolite assessment—an evidence-based approach

AU - Cuffari, Carmelo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Ulcerative colitis (UC) and Crohn’s disease are chronic relapsing idiopathic inflammatory bowel disorders affecting over 1.7 million individuals in North America; about half have unremitting disease with symptoms of abdominal pain and diarrhea that impact patient’s quality of life and work- related productivity [1, 2]. It stands to reason that the major goal of therapy for physicians caring for patients with inflammatory bowel disease (IBD) is to achieve and sustain a long- term disease remission with effective evidence-based corticosteroid-sparing therapeutic approaches that minimize the risk of drug-related toxicity.

AB - Ulcerative colitis (UC) and Crohn’s disease are chronic relapsing idiopathic inflammatory bowel disorders affecting over 1.7 million individuals in North America; about half have unremitting disease with symptoms of abdominal pain and diarrhea that impact patient’s quality of life and work- related productivity [1, 2]. It stands to reason that the major goal of therapy for physicians caring for patients with inflammatory bowel disease (IBD) is to achieve and sustain a long- term disease remission with effective evidence-based corticosteroid-sparing therapeutic approaches that minimize the risk of drug-related toxicity.

KW - 6-Mercaptopurine metabolism

KW - Azathioprine

KW - Evidence-based

KW - Metabolite assessment

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84956709618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956709618&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1677-1_12

DO - 10.1007/978-1-4939-1677-1_12

M3 - Chapter

AN - SCOPUS:84956709618

SN - 9781493916764

SP - 145

EP - 152

BT - Medical Therapy of Ulcerative Colitis

PB - Springer New York

ER -